InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,280.88
(
0.06%
)
US TECH 100
18,175.40
(
0.82%
)
Dow Jones
38,576.53
(
-0.28%
)
Brent Oil
78.78
(
-2.51%
)
Bitcoin
69,261.17
(
2.23%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

andyshow

Send PM Follow Ignore
Followers 16
Posts 983
Boards Moderated 0
Alias Born 09/27/2013

andyshow

Re: None

Monday, 12/23/2013 1:50:56 PM

Monday, December 23, 2013 1:50:56 PM

Post# of 92948
Mention of ACTC today
Biotechnology company Advanced Cell Technology (ACT), has been recruiting subjects for phase I and II clinical trials in the United States and Europe since July 2011 to test the safety and tolerability of stem-cell-derived RPE cells in patients with dry macular degeneration at the end of 12 months.

Despite the progressive nature of the eye condition, the vision of ACT's first two subjects appears to have made persistent gains in visual acuity, according to ACT's chief scientific officer Dr Robert Lanza.

http://m.scmp.com/lifestyle/health/article/1386760/nobel-laureate-says-stem-cell-research-leading-breakthrough
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up